These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 33262066)

  • 1. Adoptive T cell therapy: Boosting the immune system to fight cancer.
    Leon E; Ranganathan R; Savoldo B
    Semin Immunol; 2020 Jun; 49():101437. PubMed ID: 33262066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future perspectives on engineered T cells for cancer.
    Posey AD; Young RM; June CH
    Trends Cancer; 2024 Aug; 10(8):687-695. PubMed ID: 38853073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
    Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
    J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the efficacy and safety of engineered T cell therapy for cancer.
    Shi H; Liu L; Wang Z
    Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
    Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK
    Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paving New Roads for CARs.
    Hyrenius-Wittsten A; Roybal KT
    Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.
    Biernacki MA; Brault M; Bleakley M
    Cancer J; 2019; 25(3):179-190. PubMed ID: 31135525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GD2 Target Antigen and CAR T Cells: Does It Take More Than Two to Tango?
    Locatelli F; Quintarelli C
    Clin Cancer Res; 2024 Aug; 30(16):3361-3363. PubMed ID: 38869449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential and promise for clinical application of adoptive T cell therapy in cancer.
    Li Y; Zheng Y; Liu T; Liao C; Shen G; He Z
    J Transl Med; 2024 May; 22(1):413. PubMed ID: 38693513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
    Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
    J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive T cell therapy: points to consider.
    Yee C
    Curr Opin Immunol; 2018 Apr; 51():197-203. PubMed ID: 29730057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [T cell-based immunotherapies in solid tumors].
    Baulu E; Dougé A; Chuvin N; Bay JO; Depil S
    Bull Cancer; 2021 Oct; 108(10S):S96-S108. PubMed ID: 34920813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of endogenous T cells for adoptive transfer.
    Yee C
    Immunol Rev; 2014 Jan; 257(1):250-63. PubMed ID: 24329802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.